Tagged Ovarian cancer drug by Amgen

Ovarian cancer drug by Amgen

Amgen’s ovarian cancer drug, Trebananib fails to pass 3rd survival trial phase

Nov 5, 2014

Amgen, the manufacturers of an ovarian cancer drug, Trebananib, are disappointed in the performance of the drug at its late-state third trial phase. Trebananib is supposed to be used alongside Paclitaxel, a che...

ovarian cancer DNA

Late stage drug for ovarian cancer by Amgen Inc fails to improve overall survival rate, reveals study

Nov 4, 2014

Trebananib, the experimental last stage platinum-resistant ovarian cancer drug by Amgen, fails to improve overall survival (OS) rate very significantly, it was revealed earlier today. Patient on whom this new d...